Silybin, at 0.5 and 1% (w/w), has been reported to significantly upregulate E-cadherin and decrease the expression of the EMT markers, vimentin and MMP-2, in transgenic mice with prostate adenocarcinomas (Singh et al., 2008). Here, MMP2 is linked to prostate adenocarcinoma.